10:05 AM EST - Correvio Pharma Corp. : Reported positive data highlighting reduced hospitalization in patients treated with Brinavess® (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), from a clinical survey assessing patients with acute AF in Belgian hospitals. As a result of this new, real world data, Brinavess received reimbursement approval from the National Institute for Health and Disability Insurance (NIHDI) in Belgium. Correvio Pharma Corp.
shares T.CORV are trading up $0.44 at $6.44.
